The active metabolite of leflunomide (A771726) has been shown by in vitro studies to be an inhibitor of CYP2C9, which is concerned with the metabolism of tolbutamide. The manufacturers advise caution if leflunomide is given with tolbutamide as increased tolbutamide levels may result.
It may be prudent to monitor blood glucose levels on concurrent use.
© 2006-2022 Last Updated On: 06/20/2022 (0)
Wait 20 seconds...!!!